Key Takeaways
- • LTZ Therapeutics completed an oversubscribed $38 million Series funding round led by GL Ventures, with participation from a sovereign wealth fund and existing shareholders, bringing total funding to approximately $130 million since the company's 2022 founding.
- • Proceeds will accelerate development of the company's Universal Myeloid Cell Engager (U-MCE™)-based immunotherapy pipeline, with focus on advancing Phase 1 clinical trials for lead asset LTZ-301 across multiple top US clinical sites and preparing IND filing and Phase 1 initiation for second asset LTZ-232.
- • LTZ-301 targets oncology and autoimmune diseases, representing the company's primary near-term clinical catalyst; LTZ-232 represents pipeline expansion within the myeloid engager platform.
- • Erin Lavelle appointed as independent board director, signaling governance strengthening at a "pivotal stage of growth" as the clinical-stage immunotherapy company advances toward potential inflection points in development.
Summary
LTZ Therapeutics, a clinical-stage biotechnology company focused on immunotherapy, announced completion of an oversubscribed $38 million financing round on May 6, 2026. The round was led by GL Ventures with substantial participation from a sovereign wealth fund and continued backing from existing investors. This capital infusion brings LTZ's total funding to approximately $130 million since its establishment in 2022, positioning the Redwood City and Shenzhen-based company for accelerated development of its proprietary platform.
The capital will be deployed to advance the company's Universal Myeloid Cell Engager (U-MCE™)-based immunotherapy pipeline. Lead asset LTZ-301, which targets oncology and autoimmune diseases, is actively enrolling patients across multiple top-tier US clinical sites in an ongoing Phase 1 study. Additionally, the company plans to execute an Investigational New Drug filing and initiate Phase 1 clinical trials for LTZ-232, representing the next asset in its platform strategy.
Robert Li, founder and chief executive officer, emphasized that the financing validates investor confidence in the company's approach to leveraging myeloid biology. "This financing empowers us to translate the potential of our Myeloid Engager Platform into tangible clinical impact for patients," Li stated, highlighting the company's focus on addressing unmet medical needs through engineered immunotherapy mechanisms.
Concurrent with the financing, LTZ appointed Erin Lavelle as an independent board director, strengthening governance as the company navigates clinical development milestones. This governance addition underscores investor confidence in management's execution capabilities at a critical inflection point for the company's clinical programs.
The capital will be deployed to advance the company's Universal Myeloid Cell Engager (U-MCE™)-based immunotherapy pipeline. Lead asset LTZ-301, which targets oncology and autoimmune diseases, is actively enrolling patients across multiple top-tier US clinical sites in an ongoing Phase 1 study. Additionally, the company plans to execute an Investigational New Drug filing and initiate Phase 1 clinical trials for LTZ-232, representing the next asset in its platform strategy.
Robert Li, founder and chief executive officer, emphasized that the financing validates investor confidence in the company's approach to leveraging myeloid biology. "This financing empowers us to translate the potential of our Myeloid Engager Platform into tangible clinical impact for patients," Li stated, highlighting the company's focus on addressing unmet medical needs through engineered immunotherapy mechanisms.
Concurrent with the financing, LTZ appointed Erin Lavelle as an independent board director, strengthening governance as the company navigates clinical development milestones. This governance addition underscores investor confidence in management's execution capabilities at a critical inflection point for the company's clinical programs.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.